The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031.
The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson’s disease)
Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.
Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e. g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.
For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.
However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N. V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.
The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson’s disease)
Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.
Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e. g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.
For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.
However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N. V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technique
- endoscopy
- biopsy
- imaging
- laboratory tests
By End Use
- hospitals
- laboratories
- others
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Bio-Rad Laboratories Inc.
- Cosara Diagnostics Pvt Ltd
- Echosens
- Meril Life Sciences Pvt. Ltd.
- PerkinElmer
- Qiagen N. V.
- Siemen’s AG
- Thermo Fisher Scientific Inc.
- Trivitron Healthcare
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE
4.1 Overview
4.1.1 Market size and forecast
4.2 imaging
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 laboratory tests
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 endoscopy
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 biopsy
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: LIVER DISEASE DIAGNOSTICS MARKET, BY END USE
5.1 Overview
5.1.1 Market size and forecast
5.2 hospitals
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 laboratories
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: LIVER DISEASE DIAGNOSTICS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Technique
6.2.3 North America Market size and forecast, by End Use
6.2.4 North America Market size and forecast, by country
6.2.4.1 U. S.
6.2.4.1.1 Market size and forecast, by Technique
6.2.4.1.2 Market size and forecast, by End Use
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Technique
6.2.4.2.2 Market size and forecast, by End Use
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Technique
6.2.4.3.2 Market size and forecast, by End Use
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Technique
6.3.3 Europe Market size and forecast, by End Use
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Technique
6.3.4.1.2 Market size and forecast, by End Use
6.3.4.2 France
6.3.4.2.1 Market size and forecast, by Technique
6.3.4.2.2 Market size and forecast, by End Use
6.3.4.3 UK
6.3.4.3.1 Market size and forecast, by Technique
6.3.4.3.2 Market size and forecast, by End Use
6.3.4.4 Italy
6.3.4.4.1 Market size and forecast, by Technique
6.3.4.4.2 Market size and forecast, by End Use
6.3.4.5 Spain
6.3.4.5.1 Market size and forecast, by Technique
6.3.4.5.2 Market size and forecast, by End Use
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Technique
6.3.4.6.2 Market size and forecast, by End Use
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Technique
6.4.3 Asia-Pacific Market size and forecast, by End Use
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Technique
6.4.4.1.2 Market size and forecast, by End Use
6.4.4.2 Japan
6.4.4.2.1 Market size and forecast, by Technique
6.4.4.2.2 Market size and forecast, by End Use
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Technique
6.4.4.3.2 Market size and forecast, by End Use
6.4.4.4 South Korea
6.4.4.4.1 Market size and forecast, by Technique
6.4.4.4.2 Market size and forecast, by End Use
6.4.4.5 Australia
6.4.4.5.1 Market size and forecast, by Technique
6.4.4.5.2 Market size and forecast, by End Use
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Market size and forecast, by Technique
6.4.4.6.2 Market size and forecast, by End Use
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Technique
6.5.3 LAMEA Market size and forecast, by End Use
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Technique
6.5.4.1.2 Market size and forecast, by End Use
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Technique
6.5.4.2.2 Market size and forecast, by End Use
6.5.4.3 South Africa
6.5.4.3.1 Market size and forecast, by Technique
6.5.4.3.2 Market size and forecast, by End Use
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Market size and forecast, by Technique
6.5.4.4.2 Market size and forecast, by End Use
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Players
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Bio-Rad Laboratories Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Cosara Diagnostics Pvt Ltd
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Echosens
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Meril Life Sciences Pvt. Ltd.
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 PerkinElmer
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Qiagen N. V.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Siemen’s AG
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Thermo Fisher Scientific Inc.
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Trivitron Healthcare
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Liver Disease Diagnostics Market,' the liver disease diagnostics market size was valued at $34.5 billion in 2021, and is estimated to reach $62.6 billion by 2031, growing at a CAGR of 6.1% from 2022 to 2031. The liver is one of the most important organs in the human body as it eliminates unwanted substances from the blood, regulates chemical levels in the body, and stores nutrients for all cellular and biological activity. The phrase'liver disease' refers to a wide range of issues that causes the liver to fail to perform its primary function. Hepatitis, cirrhosis, liver cancer, and liver abscess are examples of liver diseases. These liver diseases can be diagnosed at early stages by imaging techniques, laboratory tests, endoscopies, and biopsies. Hence, there is a huge demand by medical professionals for liver disease diagnostics.Growth of the liver disease diagnostics market size is majorly driven by a surge in the number of patients suffering from liver cancer, a rise in the prevalence of acute and chronic hepatitis B, nonalcohol-related fatty liver disease, Wilson disease, iron in hemochromatosis, and hepatocellular carcinoma. For instance, in April 2022, according to Bristol Myers & Squibb, each year, nearly 1 million people die due to hepatitis B or hepatitis C, globally. The Liver Disease Diagnostics Market Share is witnessing significant growth globally, owing to the rise in the adoption of liver disease diagnostics and visualization systems in healthcare settings, coupled with technological advancements.
An increase in alcohol consumption leads to the death of healthy liver cells and reduces the ability to generate new ones as well as leads to a buildup of fats leading to liver diseases. For instance, according to the National Center for Drug Abuse Statistics 2021, about 34.1% reported binge drinking at least once and 7.0% reported extreme binge drinking. Furthermore, in a survey conducted by the Johns Hopkins University of Maryland Baltimore, about 60.1% of the respondents reported that they increased their alcohol consumption after March 1, 2020. Thus, such a rise in high alcohol consumption is expected to lead to liver disorders and further drive the growth of the market. Hence, these factors boost the growth of the liver disease diagnostics market.
The rise in the number of research institutes globally provides growth opportunities for the market. In addition, growth in patient preference for minimally invasive surgeries, and diagnostic procedures, favorable FDA approvals & reimbursement policies in developed economies, and an increase in alcohol consumption and poor dietary habits boost the growth of the liver disease diagnostics market share.
Liver diseases have increased during the COVID-19 pandemic, owing to an increase in the consumption of alcohol and leading to the growth of the liver disease diagnostic market. For instance, according to the article of springer published in 2021, 10,242 hospital admissions for alcohol-related liver disease or pancreatitis occurred in 257 hospitals during pandemic. Out of the 10,242 hospital admissions, 6371 cases were due to alcohol-related liver disease. Fourteen percent of alcohol-related liver disease cases had alcohol hepatitis, and 72% had alcoholic liver cirrhosis. In addition, the COVID-19 pandemic led to rise in awareness regarding physical, mental, and emotional health. This, in turn, has increased awareness regarding diagnosis of liver diseases and increase in regular checkups by using liver disease diagnostics. Thus, such development is anticipated to bring stabilization and drive the growth of the liver disease diagnostic market during the forecast period.
On the basis of technique, the laboratory tests segment is expected to witness the highest CAGR during the liver disease diagnostics market forecast period, owing to the rise in the prevalence of chronic liver diseases and an increase in awareness regarding laboratory tests for diagnosis of liver diseases and hepatitis. In addition, the rise in the discovery of new laboratory tests and the increase in demand for laboratory tests drives the growth laboratory tests segment.
On the basis of end-user, the laboratories segment is expected to witness the highest CAGR during the forecast period, owing to an increase in incidences of hepatitis and a rise in awareness regarding the diagnosis of hepatitis at an early stage. The rise in healthcare expenditure also boosts the growth of the laboratories segment in the liver disease diagnostics industry.
Depending on the region, Asia-Pacific Liver Disease Diagnostics Industry is expected to witness the highest CAGR during the forecast period, owing to a surge in the geriatric population that is more prone to diseases and a rise in awareness regarding liver disease diagnostics assisted minimally invasive surgeries.
KEY FINDINGS OF THE STUDY
By technique, the imaging segment held the largest share in the liver disease diagnostics market forecast in 2021.On the basis of end-user, the hospital's segment held the largest market share in 2021.
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Liver Disease Diagnostics Market Analysis from 2021 to 2031 to identify the prevailing global liver disease diagnostics market opportunities.
On the basis of region, North America held the largest market share in 2021.
The report includes an analysis of the regional as well as Liver Disease Diagnostics Market Trends, key players, market segments, technique areas, and market growth strategies.
Companies Mentioned
- Abbott Laboratories
- Bio-Rad Laboratories Inc.
- Cosara Diagnostics Pvt Ltd.
- Echosens
- Meril Life Sciences Pvt. Ltd.
- Perkinelmer
- Qiagen N.V.
- Siemen's AG
- Thermo Fisher Scientific Inc.
- Trivitron Healthcare
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 203 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 34520.4 million |
| Forecasted Market Value ( USD | $ 61962.1 million |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
